Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 82.44% is in line with its 5-year average of 77.16%, near the high end of its 5-year range (-27036.20%–100.00%).
4.73% below its 12-month average of 86.53%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 69.68%.
GROSS MARGIN
82.44%
GROSS MARGIN AVG TTM
86.53%
GROSS MARGIN AVG 3Y
84.88%
GROSS MARGIN AVG 5Y
77.16%
GROSS MARGIN AVG 10Y
35.27%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.73%
CURRENT VS 3Y AVG
-2.87%
CURRENT VS 5Y AVG
+6.85%
CURRENT VS 10Y AVG
+133.73%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+92.12%
vs the sector median at left
Atara Biotherapeutics, Inc.
Market Cap
$84.70M
Gross Margin
82.44%
TTM Avg
86.53%
3Y Avg
84.88%
5Y Avg
77.16%
Market Cap
$84.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$84.00M
Gross Margin
-736.46%
TTM Avg
-368.23%
3Y Avg
-290.99%
5Y Avg
-1574.61%
Market Cap
$83.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$87.86M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$81.22M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$88.21M
Gross Margin
40.32%
TTM Avg
35.69%
3Y Avg
34.43%
5Y Avg
37.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.70M | 82.44% | 86.53% | 84.88% | 77.16% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -736.46% | -368.23% | -290.99% | -1574.61% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 46.51% | 45.81% | 42.58% | 41.06% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 100.00% | 100.00% | 100.00% | 100.00% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 40.32% | 35.69% | 34.43% | 37.90% |
| electroCore, Inc. (ECOR)vs › | $91.33M | 87.06% | 85.86% | 83.85% | 76.72% |
Gross Margin
82.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 69.68% |
| 2026-03-31 | 75.97% |
| 2025-12-31 | 93.48% |
| 2025-09-30 | 96.67% |
| 2025-06-30 | 96.85% |
| 2025-03-31 | 79.18% |
| 2024-12-31 | 79.25% |
| 2024-09-30 | 81.08% |
| 2024-06-30 | 83.84% |
| 2024-03-31 | 92.74% |
| 2023-12-31 | 25.68% |
| 2023-09-30 | -22.31% |
| 2023-06-30 | -202.51% |
| 2023-03-31 | 82.38% |
| 2022-12-31 | -27036.20% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | -924.92% |
| 2021-12-31 | -948.41% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | -1669.38% |
| 2021-03-31 | -1703.46% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
